GlassScriptPhysician profile
Mohammad O Iqbal
NPI 1043226574
$7,832.03
in general payments reported to CMS, 2019-2025
45 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $397 · 2021: $626 · 2022: $1,663 · 2023: $1,549 · 2024: $1,647 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,445 · Education: $26.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,445.17 |
| Education | $26.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $886.46 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $780.32 | 2022-2025 | |
| Glaxosmithkline, LLC. | $762.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $754.25 | 2019-2025 | |
| Novo Nordisk INC | $710.64 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $488.97 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $475.57 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.30 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $295.95 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $224.71 | 2020-2025 | Verquvo, Belsomra, Capvaxive |
| Pfizer INC. | $222.91 | 2019-2025 | |
| Hikma Pharmaceuticals USA | $165.08 | 2019-2023 | Mitigare, Ryaltris, Kloxxado |
| Abbvie INC. | $146.65 | 2023-2025 | |
| United Therapeutics Corporation | $125.73 | 2022 | |
| Ardelyx, INC. | $124.18 | 2023-2025 | Ibsrela |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.